Navigation Links
U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent
Date:3/18/2009

Novel Stent Platform Designed for Radial Strength, Flexibility

HOUSTON, March 18 /PRNewswire/ -- IDEV Technologies Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive technologies, announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for a multi-center clinical trial of its SUPERA stent, a novel stent platform designed for the treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA). PAD affects more than 8 million people in the U.S. alone and, by the age of 65, 12-20 percent of the population will develop PAD, according to the American Heart Association.

The SUPERB trial (Comparison of the SUPERA PERipheral System to a Performance Goal Derived from Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery), a prospective, single-arm trial of 258 subjects at up to 40 U.S. sites, will be led by national co-principal investigators Kenneth Rosenfield, M.D., of Massachusetts General Hospital, Boston, MA and Lawrence Garcia, M.D., of Caritas St. Elizabeth's Medical Center, Boston, MA.

"The approval of this IDE marks a significant step forward toward understanding the potential benefits of the unique properties of the SUPERA stent," Dr. Rosenfeld said. "Members of the physician community have already shown a high level of interest in this novel stent platform and IDEV's commitment to generating prospective clinical data will help us demonstrate the promise of this device."

The objective of the trial is to demonstrate the safety and effectiveness of the SUPERA Interwoven Self-Expanding Nitinol Stent in treating subjects with obstructive SFA disease. SUPERA has demonstrated superior properties in engineering tests compared to nitinol laser cut slotted tube stents resulting in greater than four times the radial s
'/>"/>

SOURCE IDEV Technologies, Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration
2. Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds
3. ISTA Pharmaceuticals New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
4. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
5. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
6. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
7. New AAHC Toolkit Available to Optimize Clinical Research Administration
8. New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
9. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
10. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Spanien, September 2, 2014 ... Das auf dem ESC-Kongress 2014 präsentierte ... Behandlung und Behandlungsergebnisse von schlaganfallgefährdeten Patienten ... Die Daten der ... Patienten, einer innovativen und unabhängigen Forschungsinitiative ...
(Date:9/2/2014)... September 2, 2014 , ... 2014 provide insight into treatment and outcomes of ... practice --   Data from nearly ... in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, independent ... strategies for atrial fibrillation (AF) patients remain sub-optimal ...
(Date:9/2/2014)... , Sept. 2, 2014 Particle Sciences, the ... its investment in development and manufacturing capabilities with the ... Karl Mueller , Particle Sciences, Associate Director Clinical Production, ... adding clean room square footage, equipment and staff across ... The company now has over 6000ft 2 of ...
Breaking Medicine Technology:Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2
... , ... The Gamida Cell-Teva Joint Venture,(JV) announced today that the ... registration, Phase,III clinical trial of StemEx (called ExCell) and has recommended ... data analysis is,anticipated to take place during Q2 2010. StemEx is ...
... , Feb. 9 CareFusion Corp. (NYSE: ... from continuing operations for the three and six months ended ... during our second quarter and performed ahead of our expectations," said ... spending made modest improvements during the quarter and we continued to ...
Cached Medicine Technology:Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 2Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 3CareFusion Reports Second Quarter Results 2CareFusion Reports Second Quarter Results 3CareFusion Reports Second Quarter Results 4CareFusion Reports Second Quarter Results 5CareFusion Reports Second Quarter Results 6CareFusion Reports Second Quarter Results 7CareFusion Reports Second Quarter Results 8CareFusion Reports Second Quarter Results 9CareFusion Reports Second Quarter Results 10CareFusion Reports Second Quarter Results 11CareFusion Reports Second Quarter Results 12CareFusion Reports Second Quarter Results 13CareFusion Reports Second Quarter Results 14CareFusion Reports Second Quarter Results 15CareFusion Reports Second Quarter Results 16CareFusion Reports Second Quarter Results 17CareFusion Reports Second Quarter Results 18
(Date:9/2/2014)... State University biochemists have discovered a family of proteins ... aureus , a pathogenic bacterium that can cause more ... Geisbrecht, professor of biochemistry and molecular biophysics, and Kasra ... , which is the cause of increasing common staph ... Proceedings of the National Academy of Sciences , or ...
(Date:9/2/2014)... have made it clear that a mother,s eating habits ... a profound impact on her offspring and their propensity ... now, the mechanisms behind this phenomenon were unclear. According ... of The FASEB Journal F , scientists ... a mother,s diet and an offspring,s risk of future ...
(Date:9/2/2014)... Many people believe that marijuana is not addictive, but ... people are able to obtain and consume cannabis legally ... are less likely to perceive it as addictive or ... General Hospital,s Center for Addiction Medicine, said in a ... use can have significant consequences, and we know that ...
(Date:9/2/2014)... Malvern, PA (PRWEB) September 02, 2014 ... healthcare communications and education, is proud to announce the ... and clinical resource center designed for healthcare professionals who ... website offers practitioners comprehensive access to:, , ... , Dedicated topic centers for diabetes, oncology, ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Healthcare professionals ... and most complete oncology guidelines available at the point ... and the National Comprehensive Cancer Network® ... other evidence and guidelines in the content available from ... , NCCN, a not-for-profit alliance of 25 of the ...
Breaking Medicine News(10 mins):Health News:Biochemists find new treatment options for staph infections, inflammatory diseases 2Health News:How genes link a mother's diet to the risk of obesity in her offspring 2Health News:'Pot Addiction' May Be Real, Study Suggests 2Health News:HMP Communications Holdings, LLC, Acquires Nutrition411.com 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 3Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 4
... growth of cancer cells in lab study , THURSDAY, Nov. ... form of leukemia holds promise as a possible treatment for ... (Sprycel) is used to treat chronic myeloid leukemia. Researchers at ... drug limited the growth and invasive powers of ovarian cancer ...
... ... and his company, Nationwide Relocation Services, are enormous supporters of breast cancer ... lethal disease are growing by number, as both men and women are ... its power to assist in costumers, moves when coping with such difficult ...
... ... PDF conversion product line. PDF2Office® for iWork a new product to convert PDF to ... ... Recosoft Corporation the developer of the PDF2Office® family of products, PDF2ID® tool for InDesign®, ...
... ... are under even more pressure to perform during the swine flu ... large and small over the coming months. While some large businesses ... for their employees, many medium and smaller businesses are not protected. ...
... FREEHOLD, N.J., Nov. 11 Speedus Corp. (Nasdaq: SPDE ... Graham was appointed to the Company,s Board of Directors. , ... which he founded in 1988, and has been a General ... Crosshill Debt II, L.P. since 2004. Prior to these roles ...
... Forward thinking Mayor A.C. Wharton, sees Benefit in New ... Memphis Mayor, A.C. Wharton stands up for the outstanding ... hosted by University of Tennessee Health & Science Center on ... Madison in Room 305. The National Bipolar Foundation has been ...
Cached Medicine News:Health News:Leukemia Drug May Help Some Ovarian Cancer Patients 2Health News:Nationwide Relocation Services Support Breast Cancer Awareness 2Health News:Nationwide Relocation Services Support Breast Cancer Awareness 3Health News:PDF2Office for iWork -- New Utility to Convert PDF Files Directly to Native Keynote & Pages '08/'09 Formats Ships 2Health News:PDF2Office for iWork -- New Utility to Convert PDF Files Directly to Native Keynote & Pages '08/'09 Formats Ships 3Health News:How to Survive Recession and Swine Flu Outbreak in Your Employees 2Health News:Speedus Corp. Names Stephen X. Graham to Board of Directors 2Health News:Memphis Mayor Endorses National Bipolar Foundation 2
... PowerSuite holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... perfecting mini-invasive endoscopic methods for ensuring extremely ... considerable social impact. The use of these ... and represents a valid backup in cutting ... family of Nd:YAG lasers is growing, developing ...
... hair removal for all skin ... Used for leg and facial ... Offers a large spot sizes ... fast treatment. An optional ...
Medicine Products: